Target capture next-generation sequencing (NGS) for use in molecular-based research of myeloid measurable residual disease (MRD)

This study evaluated the suitability of the SureSeq™ Myeloid MRD Complete NGS Workflow Solution V2 for detection of low-level variants in measurable residual disease (MRD) monitoring.

The results show that the SureSeq™ Myeloid MRD Complete NGS Workflow Solution V2:

• Delivers high depth and uniformity of coverage for all targeted genes and genomic regions, allowing for confident detection of low frequency variants
• Can be reliably used to detect AML relevant gene specific variants SNVs, indels and FLT3-ITDs down to a possible 0.01% VAF

In summary, this indicates OGT's approach provides researchers with the capability to use capture-based NGS technology to simultaneously characterise AML gene variants in MRD monitoring.